Kenitinib

N/A

Report date: 2025/04/18 16:05:58
NME

Base Information

Drug NameKenitinib
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEpidermal growth factor receptor erbB1 inhibitorsTyrosine-protein kinase BTK inhibitors
TargetsEpidermal growth factor receptor erbB1Tyrosine-protein kinase BTK
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungLymphoma, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesSuzhou Teligene Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSuzhou Teligene Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungLymphoma, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A